Version in force , Modified +43 −8§
Amended by Regulation (EC) No 1272/2008 32008R1272 on EUR-Lex (external, EUR-Lex)
Explanation, written by a model and checked against the cited text
The list of purposes for dossiers in the introduction now describes the identification item as covering CMRs, PBTs, vPvBs, or a substance of equivalent concern in accordance with Article 59, whereas the earlier version described this item as covering PBTs, vPvBs, or a substance of equivalent concern without mentioning CMRs or Article 59 there.
The remainder of the Annex, including the content-of-dossiers section, is unchanged in substance between the two versions.
Cited: Annex XV, v1 (external, EUR-Lex) · Annex XV, v2 (external, EUR-Lex)
v1 is the previous version, v2 this one.
Text from EUR-Lex, before and after
Previous version, in force 12 October 2008 02006R1907-20081012 → this version, in force 20 January 2009 02006R1907-20090120
ANNEX XV
DOSSIERS
I. INTRODUCTION AND GENERAL PROVISIONS
This Annex lays down general principles for preparing dossiers to propose and justify:
harmonised classification and labelling of CMRs, respiratory sensitisers and other effects,
the identification of CMRs, PBTs, vPvBs, or a substance of equivalent concern, concern in accordance with Article 59,
restrictions of the manufacture, placing on the market or use of a substance within the Community.
The relevant parts of Annex I shall be used for the methodology and format of any dossier according to this Annex.
For all dossiers any relevant … 571 unchanged words … compared to its net costs to manufacturers, importers, downstream users, distributors, consumers and society as a whole.
Information on stakeholder consultation
Information on any consultation of stakeholders and how their views have been taken into account shall be included in the dossier.